Arrowstreet Capital
TEVA icon

Arrowstreet Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Arrowstreet Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Sell
38,900
-104,530
-73% -$3.36M ﹤0.01% 1520
2025
Q4 		$4.48M Buy
+143,430
New +$3.53M ﹤0.01% 1172
2025
Q1 		– Sell
-6,990,407
Closed -$154M – 2018
2024
Q4 		$154M Sell
6,990,407
-7,907,218
-53% -$144M 0.12% 155
2024
Q3 		$72.2M Buy
14,897,625
+9,095,106
+157% +$159M 0.06% 268
2024
Q2 		$94.3M Buy
5,802,519
+4,570,086
+371% +$70.4M 0.08% 202
2024
Q1 		$17.4M Sell
1,232,433
-2,770,223
-69% -$34.9M 0.02% 532
2023
Q4 		$41.8M Buy
4,002,656
+56,706
+1% +$529K 0.04% 294
2023
Q3 		$40.2M Buy
+3,945,950
New +$36.7M 0.05% 276
2023
Q1 		– Sell
-36,489
Closed -$333K – 1524
2022
Q4 		$333K Sell
36,489
-1,651,666
-98% -$14.4M ﹤0.01% 1188
2022
Q3 		$13.6M Sell
1,688,155
-803,788
-32% -$7.11M 0.02% 456
2022
Q2 		$18.7M Buy
2,491,943
+463,456
+23% +$4.04M 0.03% 388
2022
Q1 		$19M Buy
2,028,487
+1,835,952
+954% +$15.3M 0.02% 408
2021
Q4 		$1.54M Buy
+192,535
New +$1.74M ﹤0.01% 1071
2021
Q1 		– Sell
-834,320
Closed -$8.05M – 2531
2020
Q4 		$8.05M Sell
834,320
-2,565,487
-75% -$24.6M 0.01% 975
2020
Q3 		$30.6M Sell
3,399,807
-1,478,630
-30% -$15.6M 0.05% 398
2020
Q2 		$60.2M Buy
4,878,437
+2,218,983
+83% +$25.1M 0.11% 166
2020
Q1 		$23.9M Buy
+2,659,454
New +$27.2M 0.07% 262
2019
Q3 		– Sell
-788,086
Closed -$7.27M – 1712
2019
Q2 		$7.27M Buy
+788,086
New +$9.5M 0.02% 553
2019
Q1 		– Sell
-2,421,092
Closed -$37.3M – 1904
2018
Q4 		$37.3M Buy
2,421,092
+1,869,786
+339% +$38.3M 0.1% 218
2018
Q3 		$11.9M Buy
+551,306
New +$12.8M 0.03% 387
2016
Q3 		– Sell
-231,286
Closed -$11.6M – 1627
2016
Q2 		$11.6M Buy
+231,286
New +$12.3M 0.04% 394
2016
Q1 		– Sell
-509,420
Closed -$33.4M – 1528
2015
Q4 		$33.4M Sell
509,420
-1,388,048
-73% -$85.8M 0.15% 138
2015
Q3 		$107M Sell
1,897,468
-25,116
-1% -$1.63M 0.51% 39
2015
Q2 		$114M Buy
+1,922,584
New +$119M 0.64% 34
2015
Q1 		– Sell
-6,853,633
Closed -$394M – 1223
2014
Q4 		$394M Buy
6,853,633
+4,781,313
+231% +$266M 2.25% 1
2014
Q3 		$111M Buy
2,072,320
+2,005,706
+3,011% +$106M 0.6% 37
2014
Q2 		$3.49M Buy
+66,614
New +$3.4M 0.02% 482
2014
Q1 		– Sell
-270,654
Closed -$10.8M – 1341
2013
Q4 		$10.8M Buy
270,654
+104,421
+63% +$4.11M 0.06% 280
2013
Q3 		$6.28M Buy
+166,233
New +$6.48M 0.04% 339

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's TEVA Position: Q1 2026 in Review

Arrowstreet Capital reduced its Teva Pharmaceuticals (TEVA) stake by 73% in Q1 2026, selling an estimated $3.36M and leaving 38,900 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

Arrowstreet Capital first reported a position in TEVA in Q3 2013 and has held it in 29 quarters since. The position peaked at $394M in Q4 2014. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Arrowstreet Capital held 38,900 shares of Teva Pharmaceuticals worth $1.17M as of Q1 2026.
  • Arrowstreet Capital sold 104,530 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.36M.
  • Teva Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1520 holding.
  • Arrowstreet Capital first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 29 quarters since.
  • Arrowstreet Capital's Teva Pharmaceuticals position peaked at $394M in Q4 2014.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.